Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension studyHeinz Gisslinger, Jiřı́ Schwarz, Árpád Illés et al.|The Lancet Haematology|2020Cited by 351
Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study ResultsHeinz Gisslinger, Christoph Klade, Veronika Buxhofer‐Ausch et al.|Blood|2018Cited by 18
Impact of platelets on major thrombosis in patients with a normal white blood cell count in essential thrombocythemiaVeronika Buxhofer‐Ausch, Heinz Gisslinger, Dominik Wolf et al.|European Journal Of Haematology|2020Cited by 16
PS1470 EFFICACY AND SAFETY OF ANAGRELIDE IN OLDER PATIENTS WITH ESSENTIAL THROMBOCYTHEMIAVeronika Buxhofer‐Ausch, Heinz Gisslinger, Michael Steurer et al.|HemaSphere|2019Cited by 0